Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Exhibit 10.5

AndyHillCancerResearchEndowment Grant Award Agreement

This agreement (“Agreement”) is entered into by the Andy Hill Cancer Research Endowment (CARE) Fund, (“Grantor”), a grantmaking entity of the state of Washington, and Aptevo Therapeutics Inc.(“Grantee”), having an administrative office at 2401 4thAvenue Suite 1050, Seattle, WA 98121 and the USFederalTaxIdentificationNumber[***].TheGrantorhasdelegatedcertainresponsibilitiesto Grantor’s Program Administrator (“Administrator”) as described in this Agreement;

Grantor is authorized by statute of the state of Washington to make grants for the fundamental government purpose of promoting cancer research utilizing the best science and technology with the greatestpotentialtoimprovehealthoutcomes,leveragingthestate’sexistingcancerresearchfacilities and talent, creating jobs, and encouraging investments that will advance the biotech, medical device, and health care information technology industries in Washington State;

…

LEGAL_US_E # 190655141.8

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Execution Version

Exhibit 10.4

Aptevo Therapeutics Inc.

INVESTOR RIGHTS AGREEMENT

This Investor Rights Agreement (this “Agreement”) is made as of May 25, 2026, by and between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and Niowave, Inc., a Michigan corporation (“Niowave”).

WHEREAS, concurrently herewith, Niowave and the Company’s wholly owned subsidiary, Aptevo Research and Development LLC, a Delaware limited liability company (“Aptevo Research and Development”), have entered into a Collaboration Agreement (the “Collaboration Agreement”) pursuant to which they have established a collaboration with respect to certain of the Company’s product development programs;

WHEREAS, concurrently herewith, the Company and Niowave have entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) pursuant to which Niowave has agreed to purchase from the Company the Initial Shares (as defined in the Purchase Agreement) of the Company’s common stock, par value $0.001 per share (“Common Stock”), and may elect to purchase additional shares of Common Stock in the future; and

WHEREAS, the Company and Niowave wish to set forth in this Agreement certain terms and conditions regarding Niowave’s ownership of Common Stock and certain other matters as set forth in this Agreement.

…

LEGAL_US_E # 190655142.8

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Execution Version

Exhibit 10.3

APTEVO THERAPEUTICS INC.

COMMON STOCK PURCHASE AGREEMENT

This Common Stock Purchase Agreement (this “Agreement”) is dated as of May 25, 2026, by and between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and Niowave, Inc., a Michigan corporation (“Niowave”).

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Niowave, and Niowave desires to purchase from the Company, shares of common stock of the Company as more fully described in this Agreement; and

WHEREAS, concurrently herewith, the Company’s wholly owned subsidiary, Aptevo Research and Development LLC, a Delaware limited liability company (“Aptevo Research and Development”), and Niowave have entered into a Collaboration Agreement (the “Collaboration Agreement”), and the Company and Niowave have entered into an Investor Rights Agreement (the “Investor Rights Agreement”).

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and Niowave agree as follows:

ARTICLE 1

DEFINITIONS

1.1

…

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Exhibit 10.2

SUPPLY AGREEMENT

by and between

Aptevo Research and Development LLC

and

Niowave, Inc.

---

SUPPLY AGREEMENT

This Collaboration and Supply Agreement (this “Agreement”) dated as of May [22], 2026 (the “Signing Date”), is made by and between Aptevo Research and Development LLC, a Delaware corporation having a place of business at 2401 4thAve., Suite 1050, Seattle, WA 98121, USA (“Company”), and Niowave, Inc., a Michigan corporation having a place of business at 1012 N. Walnut Street, Lansing, MI 48906, USA (“Niowave” and, together with the Company, the “Parties” and each, a “Party”). Company desires to purchase from Niowave, and Niowave desires to supply Company, the Materials for Company’s use in manufacturing radiopharmaceutical products in accordance with the terms and conditions set out herein.

NOW THEREFORE in consideration of the undertakings contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows.

…

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. The omitted information is (i) not material and (ii) of the type that the Registrant treats as private and confidential.

Execution Version

Exhibit 10.1

COLLABORATION AGREEMENT

This Collaboration Agreement (this “Agreement”) is entered into as of this 25th day of May, 2026 (the “Effective Date”), by and between Aptevo Research and Development LLC, a limited liability company existing under the laws of Delaware, having a place of business at 2401 4thAvenue, Suite 1050, Seattle, WA 98121 USA (“Aptevo”), and Niowave, Inc., a Michigan corporation, having a place of business at 1012 N. Walnut Street, Lansing, MI 48906 (“Niowave”). Each of Aptevo and Niowave may be referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, Aptevo has developed certain proprietary molecules for therapeutic uses in humans;

WHEREAS, Niowave has developed certain proprietary radioisotopes for therapeutic uses in humans;

WHEREAS, the Parties desire to collaborate in a 50/50 cost and revenue sharing arrangement to develop products which combine Aptevo’s proprietary molecules and Niowave’s proprietary radioisotopes;

WHEREAS, the Parties are willing to commit specific resources and funds to support each Party’s portion of the research and development activities described in a Development Plan (as defined herein), such activities to be performed by the Parties in collaboration under this Agreement.

…

** **

EXCLUSIVE BROKER-DEALER AND LEAK-OUT MANAGEMENT AGREEMENT

This Exclusive Broker-Dealer and Leak-Out Management Agreement (this “Agreement”) is made and entered into as of the 30th day of July, 2026 between Chardan Capital Markets LLC (“Broker-Dealer”) and Zapata Quantum Inc. (the “Company,” which term includes any subsidiary of the Company that Broker-Dealer has agreed in writing to include within the scope of this Agreement).

WHEREAS, each of the sellers as listed hereto on Exhibit B (each, a “Seller” and collectively, the “Sellers”) is bound by Universal Resale and Registration Provisions attached as Exhibit A hereto (together referred to herein as the “Leak-Out Agreement”);

WHEREAS, the Company wishes to engage Broker-Dealer as the exclusive broker-dealer and management agent to sell up to 309,000,000 shares of the Company’s common stock (the “Common Stock” and, such shares, the “Restricted Shares”) held by the Sellers in accordance with the Leak-Out Agreement; and

NOW THEREFORE, in consideration of the mutual promises made herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

…

NOTE EXTENSION AGREEMENT

THIS NINTH NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of June 18, 2026, by and between 1847 Holdings LLC, a Delaware limited liability company (the “Maker”), and Target Capital 15 LLC (the “Holder”).

RECITALS

WHEREAS, the Maker and the Holder entered into that certain 20% OID Subordinated Note, dated as of March 4, 2024, for the principal amount of $1,250,000, which was amended pursuant to (i) an Amended and Restated Note, dated as of March 27, 2024, pursuant to which the principal amount was increased to $1,562,500, (ii) a Second Amended and Restated Note, dated as of April 9, 2024, pursuant to which the principal amount was increased to $2,500,000, (iii) a Third Amended and Restated Note, dated as of June 24, 2024, pursuant to which the maturity date was extended to August 20, 2024 and the principal amount was increased to $3,750,000, (iv) a Fourth Note Extension Agreement, dated as of August 20, 2024, pursuant to which the maturity date was extended to November 30, 2024 and the principal amount was increased to $4,250,000, (v) a Fifth Note Extension Agreement, dated November 15, 2024, pursuant to which the maturity date was extended to December 31, 2024 and the principal amount was changed to $2,681,610 following a partial repayment, (vi) a Sixth Note Extension Agreement, dated December 16, 2024, pursuant to which the maturity date was extended to March 31, 2025, and the principal amount was increased to $3,217,932, (vii) a Seventh Note Extension Agreement, dated March 31, 2025, pursuant to which

…

NEXPOINT DIVERSIFIED REAL ESTATE TRUST

FORM OF RESTRICTED SHARE UNITS AGREEMENT

This RESTRICTED SHARE UNITS AGREEMENT (this “Agreement”) is made as of _____, 2026, by and between NexPoint Diversified Real Estate Trust, a Delaware statutory trust (the “Company”), and ______ (the “Participant”).

1.

Certain Definitions. Capitalized terms used, but not otherwise defined, in this Agreement will have the meanings given to such terms in the Company’s 2026 Long Term Incentive Plan (as amended from time to time, the “Plan”).

2.

Grant of RSUs. Subject to and upon the terms, conditions and restrictions set forth in this Agreement and in the Plan, the Company has granted to the Participant as of _______, 2026 (the “Date of Grant”) [●]Restricted Share Units (“RSUs”). Each RSU shall represent the right of the Participant to receive one Share.

3.

Restrictions on Transfer of RSUs. Subject to Section 16 of the Plan, neither the RSUs evidenced hereby nor any interest therein or in the Shares underlying such RSUs shall be transferable prior to payment to the Participant pursuant to Section 5hereof other than (i) by transfer by the Participant for no consideration to Immediate Family Members or to a bona fide trust, partnership or other entity controlled by and for the benefit of one or more Immediate Family Members, or (ii) by will or pursuant to the laws of descent and distribution.

4.

Vesting of RSUs.

(a)

…

NEXPOINT DIVERSIFIED REAL ESTATE TRUST

FORM OF RESTRICTED SHARE UNITS AGREEMENT (Trustee)

This RESTRICTED SHARE UNITS AGREEMENT (this “Agreement”) is made as of ______, 2026, by and between NexPoint Diversified Real Estate Trust, a Delaware statutory trust (the “Company”), and _______ (the “Participant”).

1.

Certain Definitions. Capitalized terms used, but not otherwise defined, in this Agreement will have the meanings given to such terms in the Company’s 2026 Long Term Incentive Plan (as amended from time to time, the “Plan”).

2.

Grant of RSUs. Subject to and upon the terms, conditions and restrictions set forth in this Agreement and in the Plan, the Company has granted to the Participant as of _____, 2026 (the “Date of Grant”) [●] Restricted Share Units (“RSUs”). Each RSU shall represent the right of the Participant to receive one Share subject to and upon the terms and conditions of this Agreement.

3.

Restrictions on Transfer of RSUs. Subject to Section 16 of the Plan, neither the RSUs evidenced hereby nor any interest therein or in the Shares underlying such RSUs shall be transferable prior to payment to the Participant pursuant to Section 5hereof other than (i) by transfer by the Participant for no consideration to Immediate Family Members or to a bona fide trust, partnership or other entity controlled by and for the benefit of one or more Immediate Family Members, or (ii) by will or pursuant to the laws of descent and distribution.

4.

Vesting of RSUs.

(a)

…

NEXPOINT DIVERSIFIED REAL ESTATE TRUST

FORM OF RESTRICTED SHARE UNITS AGREEMENT

This RESTRICTED SHARE UNITS AGREEMENT (this “Agreement”) is made as of _____, 2026, by and between NexPoint Diversified Real Estate Trust, a Delaware statutory trust (the “Company”), and [●] (the “Participant”).

1.

Certain Definitions. Capitalized terms used, but not otherwise defined, in this Agreement will have the meanings given to such terms in the Company’s 2023 Long Term Incentive Plan (as amended from time to time, the “Plan”).

2.

Grant of RSUs. Subject to and upon the terms, conditions and restrictions set forth in this Agreement and in the Plan, the Company has granted to the Participant as of _____, 2026 (the “Date of Grant”) [●]Restricted Share Units (“RSUs”). Each RSU shall represent the right of the Participant to receive one Share.

3.

Restrictions on Transfer of RSUs. Subject to Section 16 of the Plan, neither the RSUs evidenced hereby nor any interest therein or in the Shares underlying such RSUs shall be transferable prior to payment to the Participant pursuant to Section 5hereof other than (i) by transfer by the Participant for no consideration to Immediate Family Members or to a bona fide trust, partnership or other entity controlled by and for the benefit of one or more Immediate Family Members, or (ii) by will or pursuant to the laws of descent and distribution.

4.

Vesting of RSUs.

(a)

…

April 3, 2026

Highland Opportunities and Income Fund

NexPoint Diversified Real Estate Trust OP, L.P.

Highland Global Allocation Fund

NRESF REIT Sub II, LLC

Re: Participation Side Agreement – NSP Secured Promissory Note

Ladies and Gentlemen:

Reference is hereby made to (a) that certain Secured Promissory Note, dated as of January 16, 2026, as amended by that certain First Amendment to Secured Promissory Note and Joinder Agreement, dated as of March 25, 2026 (collectively, and as further amended, restated, supplemented or otherwise modified from time to time, the “Note”), made by NexPoint Storage Partners Operating Company, LLC, a Delaware limited liability company (together with the additional co-borrowers joined pursuant to the First Amendment, the “Borrowers”), in favor of NexPoint Real Estate Finance Operating Partnership, L.P., a Delaware limited partnership (“NREF”), in the original maximum principal amount of $40,000,000 (the “Maximum Principal Amount”), and (b) that certain Participation Agreement, dated as of March 25, 2026 (as amended, restated, supplemented or otherwise modified from time to time, the “Participation Agreement”), by and between NREF, as Seller, and The Ohio State Life Insurance Company (“OSL”), as Buyer. Capitalized terms used but not otherwise defined in this letter agreement (this “Letter Agreement”) shall have the meanings ascribed to such terms in the Note or the Participation Agreement, as the context requires. The parties to this Letter Agreement are sometimes referred to herein individually as a “Party” and collectively as the

…

LIMITEDCONSENTANDSIXTEENTHOMNIBUSAMENDMENTAGREEMENT

This Limited Consent and Sixteenth Omnibus Amendment Agreement (this “Agreement”), executed as of May 11, 2026 (the “Execution Date”), but effective May 8, 2026 (the "Effective Date") is made and entered into by and among (i) CP TOWER OWNER, LLC, a Delaware limited liability company (“CP Tower Mortgage Borrower”), and CP LAND OWNER, LLC, a Delaware limited liability company (“CP Land Mortgage Borrower,” and together with CP Tower Mortgage Borrower, collectively, “Mortgage Borrower”), (ii) CP EQUITY OWNER, LLC, a Delaware limited liability company, and CP EQUITY LAND OWNER, LLC, a Delaware limited liability company (collectively, “Mezzanine Borrower”, and together with the Mortgage Borrower, collectively, the “Borrower”), (iii) NEXPOINT DIVERSIFIED REAL ESTATE TRUST, a Delaware statutory trust (formerly known as NEXPOINTSTRATEGICOPPORTUNITIESFUND),andNEXPOINTREALESTATE

…